FindMyKOL
Clinical trialNCT06620809RecruitingPhase 1Interventional

The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders

NCT06620809 is a phase 1 interventional trial sponsored by Tongji Hospital. As of 18 Nov 2026, it is recruiting participants. It studies A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection and Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection in Neuromyelitis Optica Spectrum Disorders. The registry lists an enrollment of 69 participants at 1 site in 1 country. The registry lists a start date of 28 Mar 2025 and a primary completion date of 30 Nov 2027. One of its registered investigators has a FindMyKOL profile.

SponsorTongji Hospital →Enrollment69Neuromyelitis Optica Spectrum Disorders
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06620809
FieldValue
Registry IDNCT06620809
StatusRecruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorTongji Hospital
Enrollment69
Registered sites1
Countries1
ConditionsNeuromyelitis Optica Spectrum Disorders
DrugsA placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection and Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection
Start28 Mar 2025
Primary completion30 Nov 2027
Study completion30 Nov 2027
Last update posted21 Sept 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single-center, randomized, open-label, placebo-controlled, dose-escalation trial. The objective of this research is to evaluate the safety, tolerability, and efficacy of intrathecal administration of human-induced neural stem cell-derived extracellular vesicles (NouvSoma001) for the treatment of neuromyelitis optica spectrum disorders.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China1 site, 1 recruiting
  • Tongji Hospital Affiliated To Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei

    Chuan Qin, MDDaishi Tian, MDWei Wang, MD →
    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injectionExtracellular vesicles derived from human-induced neural stem cells for intrathecal injection
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06620809

Each answer restates registry values shown on this page.

What is NCT06620809?

NCT06620809 is a phase 1 interventional trial sponsored by Tongji Hospital. It studies A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection and Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection in Neuromyelitis Optica Spectrum Disorders.

Is NCT06620809 recruiting?

As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT06620809?

The registry names Chuan Qin, MD (principal investigator, Tongji Hospital), Dai-shi Tian, MD (principal investigator, Tongji Hospoital) and Wei Wang, MD (principal investigator, Tongji Hospoital) as overall officials.

Where does NCT06620809 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.

Which drugs does NCT06620809 study?

The registered drug and biological interventions are A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection and Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection.

When is NCT06620809 expected to complete?

The registry lists a primary completion date of 30 Nov 2027 and a study completion date of 30 Nov 2027. The sponsor last updated the record on 21 Sept 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.